Accord Healthcare will in future be able to market Shanghai Henlius Biotech’s Zercepac (trastuzumab) biosimilar in the US and Canada after the firms expanded a licensing agreement that has already allowed Accord to launch the Herceptin rival in Europe. (Also see "Accord Rolls Out Zercepac Trastuzumab Biosimilar In UK" - Generics Bulletin, 25 September, 2020.)
Initially, the partnership gave Accord rights to the HLX02 trastuzumab candidate “in the territory covering 53 countries including the UK and France in Europe, 17 countries including Saudi Arabia and the United Arab Emirates in the Middle East and North Africa, and some Commonwealth of Independent States” countries